Clinical trials with metastatic melanoma patients have shown that adding a nonselective β-AR blocker to immunotherapy improved survival rates.143 Mouse melanoma models suggest that a selective β-AR blocker targeting β2-AR with anti-PD-1 and IL-2 can optimize response and survival rates. Here, IL2 is linked to metastatic melanoma.